Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference
Business Wire 1-Apr-2019 8:00 AM
Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present
edasalonexent program data, including from the Phase 2 MoveDMD trial and
open-label extension, and the design of the Phase 3 PolarisDMD trial, at
two major medical meetings in April: the 12th UK
Neuromuscular Translational Research Conference and the 2019 Muscular
Dystrophy Association (MDA) Clinical and Scientific Conference.
Edasalonexent is in Phase 3 development for the treatment of Duchenne
muscular dystrophy (DMD).
Presentation details are as follows:
12th UK Neuromuscular Translational Research Conference,
April 4 – 5, 2019 in Newcastle upon Tyne, United Kingdom, at The Centre
for Life.
-
Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will
present "Global Phase 3 PolarisDMD Trial for Edasalonexent, an Oral
NF-kB Inhibitor in Boys with DMD"
-
Presentation held during the poster session on Thursday, April 4,
2019, from 10:00am to 11:15am GMT.
2019 MDA Clinical and Scientific Conference, April 13 – 17, 2019 in
Orlando, FL, at The Hyatt Regency Orlando.
-
Richard Finkel, M.D., Chief, Division of Neurology, Department of
Pediatrics at Nemours Children's Health System and a Principal
Investigator for the MoveDMD and PolarisDMD studies, will present
"MoveDMD Phase 2 Data Supports Design of PolarisDMD, a Phase 3 Study
of Edasalonexent, a Novel NF-kB Inhibitor"
-
Presentation held during the Poster Reception on Tuesday, April 16,
2019, in the Exhibit Hall from 6:00pm – 8:00pm EDT.
About Edasalonexent (CAT-1004)Edasalonexent (CAT-1004) is
an investigational oral small molecule that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB,
which is a key link between loss of dystrophin and disease progression
in DMD. NF-kB has a fundamental role in skeletal and cardiac muscle
disease in DMD. We are currently enrolling our global Phase 3 PolarisDMD
trial to evaluate the efficacy and safety of edasalonexent for
registration purposes. In our MoveDMD Phase 2 trial and open-label
extension, we observed that edasalonexent preserved muscle function and
substantially slowed disease progression compared to rates of change in
a control period, and significantly improved biomarkers of muscle health
and inflammation. Edasalonexent continues to be dosed in the open-label
extension of the MoveDMD trial. The FDA has granted orphan drug, fast
track, and rare pediatric disease designations and the European
Commission has granted orphan medicinal product designation to
edasalonexent for the treatment of DMD. For a summary of clinical
results, please visit www.catabasis.com.
About CatabasisAt Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy. Our global
Phase 3 PolarisDMD trial is currently enrolling boys affected by
Duchenne. For more information on edasalonexent and our Phase 3
PolarisDMD trial, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005107/en/
